Bioprocessing White Papers

  1. Laying The Foundation For Viral Safety
    10/20/2017

    Mitigating the risk of viral contamination in vaccines, cell, and gene therapies.

  2. Understanding And Defining Laboratory Capacity In Biopharma
    10/19/2017

    Examine the options available for measuring your laboratory capacity.

  3. Viral Safety In Monoclonal Antibody Manufacturing
    10/19/2017

    Experts share their unique perspectives on the various technologies to prevent, detect, and remove virus contamination.

  4. Advances In Upstream Technologies Reduce Viral-Contamination Risks
    10/18/2017

    Multilayered approach includes virus-resistant CHO cell lines, advanced filtration technologies, and careful raw material selection.

  5. Purification Of Antibody Fragments And Single Domain Antibodies With Amsphere™ A3 Protein A Resin
    10/12/2017

    The wide range of antibody fragment variants for which Amsphere A3 can be used as a capture resin is described, together with insight to the related binding mechanisms obtained via x-ray crystallography.

  6. How Fit Is Your Biopharmaceutical Manufacturing Facility?
    9/7/2017

    How a proactive approach involving predictive — rather than preventive — tools to identify deficiencies before they compound and become actual problems can result in a healthy bioprocessing facility.

  7. How To Overcome Validation Challenges In A Single-Use World
    9/7/2017

    How can end users ensure the expected level of compliance in this new world of single-use systems? The secret: shared responsibility for validation with your supply chain.

  8. Insights And Tips When Addressing Bioburden Challenges
    8/30/2017

    This white paper addresses the challenges associated with the bioburden control process involved in making mAbs or other biologicals, as well as the single-use solutions and improved ways of working that manufacturers can use to avoid microbial contamination.

  9. Bioburden: Addressing Microbial Contamination In Downstream Bioprocessing
    8/30/2017

    A discussion on the risks related to bioburden downstream processing and ways to mitigate them. Topics covered include improvements in raw material, equipment design, and chromatography resin properties.

  10. Manufacturing Process Scale-Up For Phase III
    8/15/2017

    The reality is that several manufacturability problems could be brewing that will rain down during Phase III and cause costly delays, no matter how skilled the product and process may be.